- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2017
- Public Summary Document (PSD) July 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) July 2017 PBAC Meeting - Word
Glecaprevir with pibrentasvir – July 2017
Glecaprevir with Pibrentasvir: Tablet 100 mg glecaprevir with 40 mg pibrentasvir, Maviret®
Last updated
10 January 2018